Antiandrogenic activity of resveratrol analogs in prostate cancer LNCaP cells

Journal of Andrology

Volumn 33, Issue 6, 2012, Pages 1208-1215

  Iguchi, Kazuhiro ^a   Toyama, Tomoaki ^a   Ito, Tetsuro ^a   Shakui, Toshinobu ^a   Usui, Shigeyuki ^a   Oyama, Masayoshi ^a   Iinuma, Munekazu ^a   Hirano, Kazuyuki ^a  

^a GIFU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Akt; Androgen receptor

Indexed keywords

1,3 DIMETHOXY 5 (4 METHOXYSTYRYL)BENZENE[3,5,4' TRIMETHOXYRESVERATROL]; 3 (4 HYDROXYSTYRYL) 5 METHOXYPHENOL[3 METHOXYRESVERATROL]; 3 (4 HYDROXYSTYRYL)PHENOL; 3 METHOXY 5 (4 METHOXYSTYRYL)PHENOL [3,4' DIMETHOXYRESVERATROL]; 3 STYRYLPHENOL; 4 (3,5 DIMETHOXYSTYRYL)PHENOL[3,5 DIMETHOXYRESVERATROL]; 4' O METHYLRESVERATROL; 5 (4 METHOXYSTYRYL)BENZENE 1,3 DIOL[4' METHOXYRESVERATROL]; 5 STYRYLBENZENE 1,3 DIOL[PINOSYLVINE]; ANDROGEN RECEPTOR; ANTIANDROGEN; HYDROXYL GROUP; LUCIFERASE; PICEATANNOL; PROTEIN KINASE B; RESVERATROL; STILBENE; UNCLASSIFIED DRUG;

ARTICLE; ASSAY; CELL STRAIN LNCAP; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG ISOLATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; PLASMID; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PHOSPHORYLATION; REPORTER GENE;

ANDROGEN ANTAGONISTS; CELL LINE, TUMOR; HUMANS; MALE; PHENOLS; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, ANDROGEN; STILBENES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 84874421894     PISSN: 01963635     EISSN: 19394640     Source Type: Journal    
DOI: 10.2164/jandrol.112.016782     Document Type: Article

References (22)

1. Aggarwal BB, Bhardwaj A, Aggarwal RS, Seeram NP, Shishodia S, Takada Y. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24: 2783-2840.
2. Haider UG, Roos TU, Kontaridis MI, Neel BG, Sorescu D, Griendling KK, Vollmar AM, Dirsch VM. Resveratrol inhibits angiotensin IIand epidermal growth factor-mediated Akt activation: role of Gab1 and Shp2. Mol Pharmacol. 2005;68:41-48.
3. Harada N, Atarashi K, Murata Y, Yamaji R, Nakano Y, Inui H. Inhibitory mechanisms of the transcriptional activity of androgen receptor by resveratrol: implication of DNA binding and acetylation of the receptor. J Steroid Biochem Mol Biol. 2011;123:65-70.
4. Huggins C, Hodges CV. Studies on prostatic cancer. I: The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;1:293-297.
5. Iguchi K, Fukami K, Ishii K, Otsuka T, Usui S, Sugimura Y, Hirano K. Low androgen sensitivity is associated with low levels of Akt phosphorylation in LNCaP-E9 cells. J Androl. 2012;33:660-666.
6. Iguchi K, Tatsuda Y, Usui S, Hirano K. Pamidronate inhibits antiapoptotic bcl-2 expression through inhibition of the mevalonate pathway in prostate cancer PC-3 cells. Eur J Pharmacol. 2010;641:35-40.
7. Iliya I, Tanaka T, Iinuma M, Furusawa M, Ali Z, Nakaya K, Murata J, Darnaedi D. Five stilbene glucosides from Gnetum gnemonoides and Gnetum africanum. Helv Chim Acta. 2002;85:2394-2402.
8. Isaacs JT. New strategies for the medical treatment of prostate cancer. BJU Int. 2005;96(suppl 2):35-40.
9. Ito T. Structures of oligostilbenoids in dipterocarpaceaeous plants and their biological activities. Yakugaku Zasshi. 2011;131:93-100.
10. Ito T, Abe N, Oyama M, Iinuma M. Absolute structures of Cglucosides of resveratrol oligomers from Shorea uliginosa. Tetrahedron Lett. 2009;50:2516-2520.
11. Ito T, Endo H, Oyama M, Iinuma M. Novel isolation of stilbenoids with enantiomeric and meso forms from a cyperus rhizome. Phytochem Lett. 2012;5:267-270.
12. Ito T, Masuda Y, Abe N, Oyama M, Sawa R, Takahashi Y, Chelladurai V, Iinuma M. Chemical constituents in the leaves of Vateria indica. Chem Pharm Bull. 2010;58:1369-1378.
13. Jones SB, DePrimo SE, Whitfield ML, Brooks JD. Resveratrolinduced gene expression profiles in human prostate cancer cells. Cancer Epidemiol Biomarkers Prev. 2005;14:596-604.
14. Lin HK, Hu YC, Yang L, Altuwaijri S, Chen YT, Kang HY, Chang C. Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase/Akt pathway in prostate cancer LNCaP cells with different passage numbers. J Biol Chem. 2003; 278:50902-50907.
15. Mitchell SH, Zhu W, Young CY. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 1999;59:5892-5895.
16. Miyamoto H, Marwah P, Marwah A, Yang Z, Chung CY, Altuwaijri S, Chang C, Lardy H. Identification of steroid derivatives that function as potent antiandrogens. Int J Cancer. 2005;117:866-872.
17. Otsuka T, Iguchi K, Fukami K, Ishii K, Usui S, Sugimura Y, Hirano K. Androgen receptor W741C and T877A mutations in AIDL cells, an androgen-independent subline of prostate cancer LNCaP cells. Tumour Biol. 2011;32:1097-1102.
18. Shi WF, Leong M, Cho E, Farrell J, Chen HC, Tian J, Zhang D. Repressive effects of resveratrol on androgen receptor transcriptional activity. PLoS One. 2009;4:e7398.
19. Shukla Y, Singh R. Resveratrol and cellular mechanisms of cancer prevention. Ann N Y Acad Sci. 2011;1215:1-8.
20. Theron EJ, Albrecht CF, Kruger PB, Jenkins K, van der Merwe MJ. b-Glucosidase activity in fetal bovine serum renders the plant glucoside, hypoxoside, cytotoxic toward B16-F10-BL-6 mouse melanoma cells. In Vitro Cell Dev Biol Anim. 1994;30A:115-119.
21. Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, Wongvipat J, Smith-Jones PM, Yoo D, Kwon A, Wasielewska T, Welsbie D, Chen CD, Higano CS, Beer TM, Hung DT, Scher HI, Jung ME, Sawyers CL. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324: 787-790.
22. Wang Y, Romigh T, He X, Orloff MS, Silverman RH, Heston WD, Eng C. Resveratrol regulates the PTEN/AKT pathway through androgen receptor-dependent and -independent mechanisms in prostate cancer cell lines. Hum Mol Genet. 2010;19:4319-4329.